Table 3.
Overview of direct-acting antiviral-containing treatments for hepatitis C virus genotype-3-infected patients
| Drug combination | Recommendations1 | Duration | Ref. |
| IFN-containing treatment | |||
| PEG-IFN/RBV and SOF | For treatment-experienced patients, with or without cirrhosis | 12 wk | [97] |
| PEG-IFN/RBV and DCV | Not yet recommended | 12 or 16 wk | [98] |
| IFN-free treatment | |||
| SOF and RBV | Suboptimal in treatment-experienced cirrhotic patients | 24 wk | [99,100] |
| SOF and DCV | For patients without cirrhosis | 12 wk | [101] |
| SOF/DCV and RBV | For treatment-naive and treatment-experienced patients with cirrhosis | 24 wk | [102] |
| SOF/ledipasvir (single-tablet regimen) | Not yet recommended | 12 wk | [104] |
| Promising therapeutic option | |||
| GS-5816/SOF ± RBV | Under evaluation | 12 wk | [107,108] |
1
According to the EASL Clinical Practice Guidelines in April 2015[10].